ANDA 213317, held by Xiromed. Ethinyl Estradiol; Norethindrone Acetate.
As of Nov 16, 2026, ANDA 213317 (Gemmily), held by Xiromed, was first approved by FDA on Nov 9, 2020, with 2 approved supplements and 0 published complete response letters.
1 INDICATION S AND USAGE Gemmily is indicated for use by females of reproductive age to prevent pregnancy. The efficacy of Gemmily in women with a body mass index (BMI) of more than 35 kg/m 2 has not been evaluated. Gemmily i s an estrogen/progestin COC indicated for use by women to prevent pregnancy The efficacy of Gemmily in women with a body mass index (BMI) of > 35 kg/m 2 has not been evaluated ( 1, 8.8 )
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 9, 2020 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Gemmily0.02MG;1MG · capsule;oral | Ethinyl Estradiol; Norethindrone Acetate | Rx |
| Jun 13, 2024 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jun 13, 2024 | Supplement 3Labeling · Standard review | Approved | None posted |
| Nov 9, 2020 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters